The pharmacological agent outperforms current drugs in most of cases, show multiple experiments
A new pharmacological agent demonstrates promising results for the prevention of a wide range of heart rhythm disorders, including both cardiac and brain injury-induced arrhythmias. Furthermore, the compound (SS-68) demonstrates significant activity in conditions of reduced blood flow to the heart caused by obstructed arteries.
Each year, more than 17 million people from around the globe (mostly Europe and the USA) die of cardiovascular diseases and related complications, according to the World Health Organization. In Russia, about 3 out of 1,000 people suffer from the most common and malignant heart rhythm disorder: atrial fibrillation (AF), where the count is expected to at least double in the next 30 years. While sometimes lacking symptoms, atrial fibrillation could generally be recognised by a racing, irregular heartbeat, dizziness, fatigue, shortness of breath and chest pain, thereby largely compromising the quality of one’s life. The disorder could also lead to various complications, including dementia, stroke and heart failure.
Currently, the drugs administered to AF patients have major deficiencies, including narrow therapeutic windows, which means that even minimal imprecision in the dosage could result in unacceptable toxicity. Hence, patients need to be closely monitored and have their doses adjusted on a regular basis.
In their study, the team turned to the aminoindole derivatives to look for an alternative compound. This chemical group has already shown a significant potential in terms of cardio-pharmacological activity.
Having tested the SS-68 compound on multiple occasions in different animals, the researchers report that it has a pronounced antiarrhythmic effect and is able to bring the electrical activity of the heart back to normal and, in most cases, outperforming the reference drugs used in clinical practice: amiodarone, lidocaine, aymaline, ethacizine, etmozine and quinidine anaprilin.
Further, in brain injury-induced arrhythmias, the compound was found to reduce the episodes of epilepsy. It was also observed to have a positive effect in clogged blood vessels where it is reported to have successfully increased the coronary blood flow. In addition, the compound managed to decrease the area of necrosis in the heart tissue caused by a heart attack.
“To date, there have been significant achievements of Russian and foreign pharmacologists, chemists and clinicians in creating and introducing into the practical medicine a number of antiarrhythmic drugs different by their chemical structure, nature, spectrum, activity and mechanism of action; nevertheless, one of the most important tasks of modern pharmacology is searching for and developing new highly active substances of the corresponding action,” explain the scientists.
“Special attention should be paid to an in-depth study of the molecular mechanisms of action of this compound,” they conclude.
A paper looking further into the molecular mechanisms of the antiarrhythmic action of SS-68 prepared by the same research team is currently in press with Research Results in Pharmacology.
The Latest on: Pharmacological agent
via Google News
The Latest on: Pharmacological agent
- Ofev (Nintedanib) Drug Insight and Market Forecast Report 2020-2030 - ResearchAndMarkets.comon October 5, 2020 at 3:26 am
The "Ofev (Nintedanib) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
- JAMA Ophthalmology Publishes Pooled Analysis of Data from two Phase 3 Clinical Trials of ...on October 1, 2020 at 10:32 am
RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (Osmotica), today announced that JAMA Ophthalmology has published pooled analysis of data from two Phase 3 ...
- Active Ingredients Market overview 2020, In-depth analysis with Impact of COVID-19, Types, Opportunities, Revenue and Forecast 2026on September 29, 2020 at 9:05 am
The Active Ingredients Market is expected to exceed more than US$ 3.0 Billion by 2024 at a CAGR of 5.0%. Active ...
- Adjunctive Pharmacologic Use in Carotid Endarterectomy: A Reviewon September 22, 2020 at 5:00 pm
With the possible exception of aspirin and dextran, the use of many pharmacologic agents before, during, and after CEA has not been standardized. Prospective randomized trials are still needed to ...
- Stress Ulcer Prophylaxis in the Postoperative Periodon September 21, 2020 at 5:00 pm
In addition, the majority of recently published prospective studies and a meta-analysis have been unable to demonstrate a reduction in clinically important bleeding with pharmacologic agents.
- ACR Publishes Guidelines for Pharmacologic and Nonpharmacologic Treatment of Gouton September 14, 2020 at 5:00 pm
Pharmacologic urate-lowering therapy should ... If at least one of these agents is contraindicated or not tolerated by the patient, an alternative first-line medication is a uricosuric agent ...
- Microengineered 3D pulmonary interstitial mimetics highlight a critical role for matrix degradation in myofibroblast differentiationon September 14, 2020 at 1:30 am
Using a multistep bioinformatics analysis of IPF patient transcriptomes and in vitro pharmacologic screening, we identify matrix metalloproteinase activity to be essential for 3D but not 2D ...
- Pipeline Review on Idiopathic Pulmonary Fibrosis - H1 2020 - ResearchAndMarkets.comon September 10, 2020 at 4:22 am
Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants ... The guide covers the descriptive pharmacological action of the therapeutics, its complete ...
- DNP in Nurse Anesthesiaon August 19, 2020 at 11:14 am
In our program, students take advantage of the core courses common to all master of science nursing specialties, learn advanced physiologic and pharmacologic principles, and gain hands-on clinical ...
via Bing News